Molecular Modeling Insights into Bioactivities of Head-to-Tail Cyclic Peptides: Potential Sedoheptulose-7-Phosphate Isomerase Inhibitors
Journal: Advanced Journal of Chemistry-Section A (Vol.7, No. 2)Publication Date: 2024-04-01
Authors : Abel Kolawole Oyebamiji; Sunday A. Akintelu; Banjo Semire; Adesoji Alani Olanrewaju; Emmanuel T. Akintayo; Cecillia O. Akintayo; Habibat Omolara Adubiaro; Oluwakemi Ebenezer; Jonathan O. Babalola;
Page : 146-162
Keywords : Peptides; Bioactive; Inhibitors; Modeling; Bacteria;
Abstract
The biological activity and properties of fourteen cyclic peptides were investigated using in silico approach. The predicted features for the studied compounds using 6-31G* via Spartan 14 software were lipophilicity, the highest occupied molecular orbital energy, the lowest occupied molecular orbital energy, HOMO/LUMO energy gap, dipole moment, molecular weight, and polar surface area. The descriptors obtained perfectly described the activities of the studied ligands. Likewise, the studied ligands were docked against sedoheptulose-7-phosphate isomerase [PDB id: 2x3y] and it was observed that all the ligands examined in this work have higher binding affinity than the ceftazidime (referenced drug) except compound 9 and 12. The predicted compounds proved to have higher binding affinities than the referenced compound and these were further confirmed using molecular dynamic simulation as well as pharmacokinetics studies.
Other Latest Articles
- Decoration of Metal Nanoparticles and Metal Oxide Nanoparticles on Carbon Nanotubes
- Impact of Annealing Temperature on Hydrothermally Synthesized Copper Antimony Oxide (Cu2Sb2O) from Amorphous Phase to Monoclinic Structure
- Black Garlic (Allium sativum L.) Ethanol Extract: Total Phenolic Content and Antioxidant Activity Test Determination Using the Soxhletation Method
- Estimation of Quality, Safety and Efficacy of Ashwagandhadi Leha Using Chromatographic Technique
- Adverse Drug Reaction (ADR) and Pharmacovigilance: A Current Prospectives
Last modified: 2024-01-13 16:32:28